Please login to the form below

Not currently logged in
Email:
Password:

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications

Merck & CoMerck & Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline.

The deal - which includes $500m upfront in cash and up to $750m if development and commercial objectives are met - gives Merck access to Afferent's pipeline of drugs that target P2X3 purinergic receptors found on nerve cells.

These receptors seem to become more common after nerve injury or inflammation, and drugs that block them are thought to have potential in a broad range of 'neurogenic' indications in which nerves become hyper-sensitised.

For Merck, the deal centres around Afferent's lead P2X3 receptor antagonist AF-219, an orally-active drug that is currently being tested in a phase IIb trial in patients with chronic or 'pathologic' cough that can last for months or even years.

Afferent estimates that persistent cough affects up to 10% of the US population, and around 17% of these people derive no benefit from current treatments such as opioid drugs and corticosteroids.

In a statement Merck's R&F head Roger Perlmutter said chronic cough represents "an area of significant unmet medical need".

Clinical data presented at the American Thoracic Society (ATS) in May showed that AF-219 significantly reduced cough frequency at a dose of 50mg twice-daily. A second phase involving lower doses will generate results later this year and Afferent has said it hopes to start a phase III programme in chronic cough next year.

In addition to chronic cough, AF-129 is also in a phase II trial for cough and breathlessness associated with the respiratory disease idiopathic pulmonary fibrosis (IPF). Meanwhile a second pipeline candidate - AF-130 - is in phase I trials for resistant high blood pressure and preclinical development for migraine.

Merck has been working on its own early-stage R&D programme in the P2X3 area, along with other big pharma companies including AstraZeneca and Shionogi. Afferent licensed its programme from Roche in 2009.

The deal ties in with a pledge by Merck chief executive Ken Frazier earlier this year that the company would step up its efforts to bolster its pipeline through licensing and acquisition deals.

Article by
Phil Taylor

10th June 2016

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics